Home/Filings/4/0001599901-24-000188
4//SEC Filing

MacLean Michael F 4

Accession 0001599901-24-000188

CIK 0001599901other

Filed

Nov 7, 7:00 PM ET

Accepted

Nov 8, 4:50 PM ET

Size

16.3 KB

Accession

0001599901-24-000188

Insider Transaction Report

Form 4
Period: 2024-11-06
MacLean Michael F
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    2024-11-06$46.22/sh27,262$1,260,01794,093 total
  • Exercise/Conversion

    Common Stock

    2024-11-06$6.57/sh+13,875$91,159107,968 total
  • Sale

    Common Stock

    2024-11-06$45.33/sh13,875$629,00894,093 total
  • Exercise/Conversion

    Common Stock

    2024-11-06$8.82/sh+65,182$574,905159,275 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-11-0665,1820 total
    Exercise: $8.82Exp: 2030-05-14Common Stock (65,182 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-11-0613,87560,125 total
    Exercise: $6.57Exp: 2033-09-10Common Stock (13,875 underlying)
  • Sale

    Common Stock

    2024-11-06$45.33/sh65,182$2,954,95494,093 total
Footnotes (5)
  • [F1]The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on July 8, 2024.
  • [F2]This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.86 to $48.01. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $48.01. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]All shares subject to this option have fully vested as of the date of this report.
  • [F5]1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of September 11, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the option shall be fully vested on the fourth anniversary of the Vesting Commencement Date.

Issuer

Avidity Biosciences, Inc.

CIK 0001599901

Entity typeother

Related Parties

1
  • filerCIK 0001383731

Filing Metadata

Form type
4
Filed
Nov 7, 7:00 PM ET
Accepted
Nov 8, 4:50 PM ET
Size
16.3 KB